Morgan Stanley Sees 2014 Guidance for Tenet Healthcare as Full of Puts and Takes
In a report published Tuesday, Morgan Stanley analyst Andrew Schenker reiterated an Equal-Weight rating on Tenet Healthcare (NYSE: THC).
In the report, Morgan Stanley noted, “THC issued FY14 Adj. EBITDA guidance of $1.8B to $1.9B including reform benefit of $50M to $100M. Guidance compares with MS est. and consensus of $1.94B and 1.96B, respectively. THC's forecast assumes pro-forma admissions growth of -2% to flat adj. admissions growth of -1% to +1% and VHS synergies of $50M-$100M. Separately, the company anticipates 1Q14 adj. EBITDA of $350M-$400M including $10M in EHR, this compares with MS and street at $434M and $447M, respectively.”
Tenet Healthcare closed on Monday at $48.33.
Latest Ratings for THC
|Jan 2016||Mizuho Securities||Upgrades||Neutral||Buy|
|Jan 2016||Wells Fargo||Downgrades||Outperform||Market Perform|
|Dec 2015||Credit Suisse||Initiates Coverage on||Neutral|
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.